Case Study

SMS for Life (B): Living the implementation challenges of a successful pilot project

8 pages
June 2011
Reference: IMD-3-2169

After successfully completing the roll-out of the SMS for Life project in three health districts in Tanzania, Jim Barrington, former group CIO of Novartis and Project Director for SMS for Life with Roll-Back Malaria, faces a number a challenges for implementing the project full scale in Tanzania as well as having other African countries (including Kenya, Ghana, The Democratic Republic of the Congo) adopt the SMS for Life project approach. This case covers the implementation efforts of Jim in these countries as well as new challenges he is facing as competitors in the pharmaceutical industry learn about the project and its use in managing the supply chains for the private distribution of drugs in Africa. In addition, new interest by NGOs is developing on “drug access” to stock in African countries as well as launching new funding formulas for the distribution of malaria and other drugs on a private and public basis. Finally, companies that help consumers distinguish between fake and genuine medicines and drugs are using SMS for Life type capabilities as well. In the winter of 2011, Jim Barrington faces important questions: 1) Where should he continue to focus his time and energy? 2) What can Novartis as a healthcare company do to compete with SMS for Life capabilities developing in both the public and private distribution of drugs in Africa? 3) What roles should business and IT leaders in Novartis play in exploiting what started as a pro bono “corporate social responsibility” pilot project in the public sector to achieve competitive value in Novartis businesses? 4) What other strategies like SMS for Life could Novartis pursue to manage “information about products” as new and emerging services in the healthcare industry?

Learning Objective

There are three learning objectives and ways to teach this case: 1) to discuss how to lead and manage a successful pilot project into a full scale roll-out in multiple countries with different stakeholders and funding approaches; 2) to understand how a project launched as a corporate social responsibility effort develops competitive value in the private sector and what the opportunities and trade-offs are for both Novartis and its competitors? And 3) to address the challenges of being involved in emerging patient-centric and information-based business initiatives for companies whose focus and operating cultures have been primarily product-based in the healthcare industry.

Keywords
Public-Private Partnership, Collaboration, Malaria, Innovation, Information Management, Supply Chain, General Management, Strategy
Settings
Africa, Switzerland
Novartis, Healthcare, Pharmaceuticals
April 2010-February 2011
Type
Field Research
Copyright
© 2011
Available Languages
English
Related material
Teaching note, Video
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]

Contact

Research Information & Knowledge Hub for additional information on IMD publications

This case study is part of a series
  • SMS for Life (A): A public-private collaboration to prevent stock-outs of life saving malaria drugs in Africa
  • SMS for Life (B): Living the implementation challenges of a successful pilot project
  • SMS for Life (C): Sustaining the initiative and leveraging its social and business value for Novartis
2013 EFMD AWARD WINNER (Best of the Best)
2013 EFMD AWARD WINNER (Responsible Leadership)
2012 SIM BEST PAPER AWARD
This case study is part of a series
  • SMS for Life (A): A public-private collaboration to prevent stock-outs of life saving malaria drugs in Africa
  • SMS for Life (B): Living the implementation challenges of a successful pilot project
  • SMS for Life (C): Sustaining the initiative and leveraging its social and business value for Novartis
Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics
SMS for Life (A): A public-private collaboration to prevent stock-outs of life saving malaria drugs in Africa
By Donald A. Marchand and Anna Moncef
Case reference: IMD-3-2168 ©2010
Summary
Malaria is a mosquito-borne infectious disease and a public health problem in over 100 countries worldwide. It causes about one million deaths each...
2013 EFMD AWARD WINNER (Best of the Best); 2013 EFMD AWARD WINNER (Responsible Leadership); 2012 SIM BEST PAPER AWARD
Reference IMD-3-2168
Copyright ©2010
Copyright owner IMD Copyright
Organization Novartis
Industry Healthcare, Pharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications

SMS for Life (B): Living the implementation challenges of a successful pilot project
By Donald A. Marchand
Case reference: IMD-3-2169 ©2011
Summary
After successfully completing the roll-out of the SMS for Life project in three health districts in Tanzania, Jim Barrington, former group CIO of N...
2013 EFMD AWARD WINNER (Best of the Best); 2013 EFMD AWARD WINNER (Responsible Leadership); 2012 SIM BEST PAPER AWARD
Reference IMD-3-2169
Copyright ©2011
Copyright owner IMD Copyright
Organization Novartis
Industry Healthcare, Pharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications

SMS for Life (C): Sustaining the initiative and leveraging its social and business value for Novartis
By Donald A. Marchand
Case reference: IMD-3-2171 ©2012
Summary
This third and final part of the "SMS for Life" case series concentrates on the institutional response to the question of how Novartis could sustai...
2013 EFMD AWARD WINNER (Best of the Best); 2013 EFMD AWARD WINNER (Responsible Leadership); 2012 SIM BEST PAPER AWARD
Reference IMD-3-2171
Copyright ©2012
Copyright owner IMD Copyright
Organization Novartis
Industry Healthcare, Pharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications